US2007037879A1PendingUtilityA1

Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease

63
Individually held — no corporate assignee on recordPriority: Dec 17, 1998Filed: Oct 18, 2006Published: Feb 15, 2007
Est. expiryDec 17, 2018(expired)· nominal 20-yr term from priority
Inventors:William J. Wechter
A61P 43/00A61P 9/08A61P 9/10A61P 35/00A61P 37/04A61P 9/04A61P 7/02A61P 9/12A61P 3/06A61P 9/00A61P 27/02A61P 25/00A61P 13/12A61P 21/00A61K 31/355A61K 45/06A61P 1/16
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is generally related to the discovery of the therapeutic benefit of administering gamma-tocopherol and gamma-tocopherol derivatives. More specifically, the use of gamma-tocopherol and racemic LLU-alpha, (S)-LLU-alpha, or gamma-tocopherol derivatives as antioxidants and nitrogen oxide scavengers which treat and prevent high blood pressure, thromboembolic disease, cardiovascular disease, cancer, natriuretic disease, the formation of neuropathological lesions, and a reduced immune system response are disclosed.

Claims

exact text as granted — not AI-modified
1 . A method for treating or preventing natriuretic-related disease, comprising orally or parentally administering a pharmaceutical composition comprising at least one compound that is metabolized in vivo to 2,7,8-trimethyl-2-(β-carboxyethyl)-6-hydroxychroman (LLU-α).  
     
     
         2 . The method of  claim 1 , wherein the at least one compound is a member of the Vitamin E family.  
     
     
         3 . The method of  claim 2 , wherein the member of the Vitamin E family is γ-tocopherol.  
     
     
         4 . The method of  claim 2 , wherein the member of the Vitamin E family is a tocotrienol.  
     
     
         5 . The method of  claim 1 , wherein the natriuretic-related disease is selected from the group consisting of hypertension, high blood pressure, ischemia, angina pectoris, congestive heart failure, cirrhosis of the liver, nephrotic syndrome, ineffective renal perfusion, and ineffective glomerular filtration.  
     
     
         6 . A method of treating or preventing a cardiovascular disease, comprising orally or parentally administering a pharmaceutical composition comprising at least one compound that is metabolized in vivo to 2,7,8-trimethyl-2-(β-carboxyethyl)-6-hydroxychroman (LLU-α).  
     
     
         7 . The method of  claim 6 , wherein the at least one compound is a member of the Vitamin E family.  
     
     
         8 . The method of  claim 7 , wherein the member of the Vitamin E family is γ-tocopherol.  
     
     
         9 . The method of  claim 7 , wherein the member of the Vitamin E family is a tocotrienol.  
     
     
         10 . The method of  claim 6 , wherein the cardiovascular disease is selected from the group consisting of thromboembolic disease, artherosclerosis, low density lipid oxidation, adhesion of monocytes to endothelial cells, foam-cell formation, fatty streak development, platelet adherence, platelet aggregation, smooth muscle cell proliferation, and reperfusion injury.  
     
     
         11 . A method of treating or preventing cancer, comprising orally or parentally administering a pharmaceutical composition comprising at least one compound that is metabolized in vivo to 2,7,8-trimethyl-2-(β-carboxyethyl)-6-hydroxychroman (LLU-α).  
     
     
         12 . The method of  claim 11 , wherein the at least one compound is a member of the Vitamin E family.  
     
     
         13 . The method of  claim 12 , wherein the member of the Vitamin E family is γ-tocopherol.  
     
     
         14 . The method of  claim 12 , wherein the member of the Vitamin E family is a tocotrienol.  
     
     
         15 . The method of  claim 11 , wherein the cancer is prostate cancer.  
     
     
         16 . A method of treating or preventing a neurological disease, comprising orally or parentally administering a pharmaceutical composition comprising at least one compound that is metabolized in vivo to 2,7,8-trimethyl-2-(β-carboxyethyl)-6-hydroxychroman (LLU-α).  
     
     
         17 . The method of  claim 16 , wherein the at least one compound is a member of the Vitamin E family.  
     
     
         18 . The method of  claim 17 , wherein the member of the Vitamin E family is γ-tocopherol.  
     
     
         19 . The method of  claim 17 , wherein the member of the Vitamin E family is a tocotrienol.  
     
     
         20 . A method of enhancing an immune response in a subject, comprising orally or parentally administering to said subject a pharmaceutical composition comprising at least one compound that is metabolized in vivo to 2,7,8-trimethyl-2-(β-carboxyethyl)-6-hydroxychroman (LLU-α).  
     
     
         21 . The method of  claim 20 , wherein the at least one compound is a member of the Vitamin E family.  
     
     
         22 . The method of  claim 21 , wherein the member of the Vitamin E family is γ-tocopherol.  
     
     
         23 . The method of  claim 21 , wherein the member of the Vitamin E family is a tocotrienol.  
     
     
         24 . A method of preventing or treating a disease caused by oxidation in vivo by administering a pharmaceutical composition comprising at least one compound that is metabolized in vivo to 2,7,8-trimethyl-2-(β-carboxyethyl)-6-hydroxychroman (LLU-α).  
     
     
         25 . The method of  claim 24 , wherein the at least one compound is a member of the Vitamin E family.  
     
     
         26 . The method of  claim 25 , wherein the member of the Vitamin E family is γ-tocopherol.  
     
     
         27 . The method of  claim 25 , wherein the member of the Vitamin E family is a tocotrienol.  
     
     
         28 . A method of reducing the formation of free radicals in a subject, comprising orally or parentally administering to said subject a pharmaceutical composition comprising at least one compound that is metabolized in vivo to 2,7,8-trimethyl-2-(β-carboxyethyl)-6-hydroxychroman (LLU-α).  
     
     
         29 . The method of  claim 28 , wherein the at least one compound is a member of the Vitamin E family.  
     
     
         30 . The method of  claim 29 , wherein the member of the Vitamin E family is γ-tocopherol.  
     
     
         31 . The method of  claim 29 , wherein the member of the Vitamin E family is a tocotrienol.

Join the waitlist — get patent alerts

Track US2007037879A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.